Latest filings (excl ownership)
15-15D
Suspension of duty to report
19 Oct 20
8-K
Medizone International Announces Filing of Voluntary Chapter 7 Bankruptcy Proceeding
11 May 18
RW
Registration withdrawal request
25 Apr 18
8-K
ALL OTHER NAMES used by debtor in the last 8 years
24 Apr 18
DEF 14A
Definitive proxy
17 Apr 18
S-1/A
IPO registration (amended)
13 Apr 18
PRE 14A
Preliminary proxy
6 Apr 18
S-1
IPO registration
3 Apr 18
8-K
Regulation FD Disclosure
27 Mar 18
RW
Registration withdrawal request
22 Mar 18
10-K
2017 FY
Annual report
20 Mar 18
S-1
IPO registration
12 Feb 18
8-K
Medizone Announces Completion of Financing
5 Feb 18
8-K
Medizone International Appoints Jude Dinges to Executive Team
1 Feb 18
8-K
Regulation FD Disclosure
5 Dec 17
10-Q
2017 Q3
Quarterly report
8 Nov 17
8-K
Medizone International Appoints Philip Theodore to Executive Team
3 Nov 17
8-K
The AsepticSureĀ® Disinfection System, a revolutionary disinfection technology, Receives CE Mark
16 Oct 17
8-K
Medizone International announces the appointment of David A. Dodd as new Chief Executive Officer
19 Sep 17
8-K
Medizone International prepares plans to submit a marketing application to FDA for use of AsepticSure as a medical device
28 Aug 17
8-K
Medizone International Announces a Change in the Board of Directors
24 Aug 17
10-Q
2017 Q2
Quarterly report
8 Aug 17
8-K
Departure of Directors or Certain Officers
22 Jun 17
8-K
Regulation FD Disclosure
8 Jun 17
8-K
Regulation FD Disclosure
31 May 17
8-K
Medizone International Continues Board of Directors Expansion to Support Executing on the Launch of AsepticSure in Key Global Markets
23 May 17
10-Q
2017 Q1
Quarterly report
12 May 17
8-K
Medizone International Announces Sales Agreement with Innovasource LLC
25 Apr 17
8-K
Medizone International prepares plans to submit AsepticSure for FDA approval as a medical device
7 Apr 17
8-K
Medizone International Expands Board of Directors to Support Executing on the Launch of AsepticSure in Key Global Markets
6 Apr 17
10-K
2016 FY
Annual report
22 Mar 17
8-K
Regulation FD Disclosure
3 Mar 17
8-K
Medizone International to Host Investor Conference Call
1 Mar 17
8-K
Medizone International announces the appointment of a new Chairman and Interim CEO
28 Feb 17
8-K/A
Amendments to Articles of Incorporation or Bylaws
27 Feb 17
8-K
Amendments to Articles of Incorporation or Bylaws
26 Jan 17
8-K
Submission of Matters to a Vote of Security Holders
19 Dec 16
10-Q
2016 Q3
Quarterly report
10 Nov 16
DEFA14A
Additional proxy soliciting materials
4 Nov 16
8-K
Unregistered Sales of Equity Securities
27 Oct 16
Latest ownership filings
4
Michael Shannon
2 Mar 18
4
Vincent C Caponi
20 Feb 18
3
Jude P. Dinges
16 Feb 18
4
David A Esposito
16 Feb 18
4
Vincent C Caponi
18 Jan 18
4
PHILIP A THEODORE
4 Jan 18
4
Stephanie Lynn Sorensen
4 Jan 18
4
DAVID A DODD
4 Jan 18
4
David A Esposito
2 Jan 18
4
Michael Shannon
2 Jan 18
4
PHILIP A THEODORE
5 Dec 17
3
PHILIP A THEODORE
30 Nov 17
4
DAVID A DODD
25 Oct 17
4
DAVID A DODD
20 Sep 17
3
DAVID A DODD
19 Sep 17
4
David A Esposito
1 Sep 17
4
David A Esposito
30 Aug 17
4
David A Esposito
28 Jun 17
4
DANIEL D HOYT
20 Jun 17
4
Stephen F Meyer
13 Jun 17
3
Stephen F Meyer
31 May 17
4
Stephen F Meyer
31 May 17
4
David A Esposito
21 Apr 17
3
Bobby Dwayne Montgomery
7 Apr 17
4
Bobby Dwayne Montgomery
7 Apr 17
4
David A Esposito
7 Apr 17
4
David A Esposito
24 Mar 17
4/A
David A Esposito
3 Mar 17
4
David A Esposito
2 Mar 17
3
Stephanie Lynn Sorensen
6 Feb 17
4
Michael Shannon
6 Feb 17
4
David A Esposito
6 Feb 17
4
EDWIN G MARSHALL
6 Feb 17
4
DANIEL D HOYT
6 Feb 17
4
Stephanie Lynn Sorensen
6 Feb 17
4
Vincent C Caponi
6 Feb 17
4
Boyd G Evans
25 May 16
3
Boyd G Evans
6 May 16
5
David A Esposito
16 Feb 16
5
Michael Shannon
16 Feb 16